Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …

Following Alzheimer's, Parkinson's disease (PD) is the second-most common
neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile …

Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy that is
associated with repetitive head impacts or exposure to blast waves. First described as punch …

Age-related neurodegenerative diseases involving amyloid aggregation remain one of the
biggest challenges of modern medicine. Alterations in the gastrointestinal microbiome play …

Recent discoveries have implicated the gut microbiome in the progression and severity of
Parkinson's disease; however, how gut bacteria affect such neurodegenerative disorders …

Neurodegenerative disorders affect around one billion people worldwide. They can arise
from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is …

The global burden of neurodegenerative diseases underscores the urgent need for
innovative strategies to define new drug targets and disease-modifying factors. The …

Protein aggregation is behind the genesis of incurable diseases and imposes constraints on
drug discovery and the industrial production and formulation of proteins. Over the years, we …

Abstract α-Synuclein is an abundant protein at the neuronal synapse that has been
implicated in Parkinson's disease for over 25 years and characterizes the hallmark …

Aggregation of amyloidogenic proteins is a characteristic of multiple neurodegenerative
diseases. Atomic resolution of small molecule binding to such pathological protein …